Mind Cure Health Inc.
CSE: MCUR, FFT: 6MH
Company Overview
- Clinical Research Technology: The company anticipates acquiring diagnostic technologies for use in clinical trials and data collection tools to help clinicians receive patient feedback to improve treatment efficacy.
- Nootropic Formulations: The company is developing nootropic, psychoactive products and substances to promote productivity and enhanced mental health, including products launched under its MoonBeam Mushroom brand.
- Clinical Research: The company intends to evaluate the potential for clinical trials that would benefit mental health and wellness under Health Canada’s industry-leading framework for psychedelic medicines.
- Product Discovery: The company is evaluating the legal and commercial viability of psychedelic compounds such as psilocybin, as well as new and improved psychedelic-inspired candidates, such as non-psychoactive analogs.
- Formulations & Supply: The company is evaluating a path to manufacture, import and supply traditional and novel pharmaceutical agents for North America to satisfy the underserved access to psychoactive compounds APIs for research.
Financial Highlights
$0
Revenue (ttm)
-$45,274
Gross Profit (ttm)
-$0.14
Diluted EPS (ttm)
Management Team
Mr. Philip Tapley
Founder, Interim CEO & Chairman
Mr. Michael Andrew Wolfe CA, CPA, M.B.A., MBA
Chief Financial Officer
Mr. Robert C. Hill C.A., CPA, CA, CPA
Independent Director & Corp. Sec.
Mr. Tarik Lebbadi
Chief Operating Officer
Daniel Kim
VP of Investor Relations
Mr. Daniel Herrera
Chief Growth Officer
Dr. Doron Sagman FRCPC, M.D.
Chief Medical Officer
Dr. Clare Purvis
Chief Product Officer
Key Highlights
Market Capitalization
$2,458,945
Shares Outstanding
45,220,000
Shares Short (% of Float)
()
Insider Ownership
5%